• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    ICON Reports First Quarter 2024 Results

    4/24/24 4:15:00 PM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Get the next $ICLR alert in real time by email

    Highlights

    • Net business wins in the quarter of $2,654 million; a net book to bill of 1.27, an increase of 9.9% on quarter one 2023.
    • Closing backlog of $23.4 billion, an increase of 2.5% on quarter four 2023 and 10.1% on quarter one 2023.
    • Quarter one revenue of $2,090.4 million representing an increase of 5.7% on prior year revenue and 5.4% on a constant currency basis.
    • Quarter one adjusted EBITDA of $444.0 million or 21.2% of revenue, an increase of 11.3% on quarter one 2023.
    • GAAP net income for the quarter of $187.4 million or $2.25 per diluted share, an increase of 59.6% on quarter one 2023 diluted earnings per share.
    • Quarter one adjusted net income was $288.5 million or $3.47 per diluted share, an increase of 19.7% on quarter one 2023 adjusted diluted earnings per share.
    • Days sales outstanding of 49 days at March 31, 2024, a decrease from 54 days at March 31, 2023, and an increase from 47 days at December 31, 2023.
    • $275.0 million repayment made on Term Loan B debt in quarter one. Net debt balance of $3.1 billion at March 31, 2024 with net debt to adjusted EBITDA ratio of 1.8x.
    • Updating full-year 2024 financial guidance with revenue in the range of $8,480 - $8,720 million, representing a year over year increase of 4.4% to 7.4%, and adjusted earnings per share* in the range of $14.65 - $15.15, representing a year over year increase of 14.5% to 18.5%. Adjusted earnings per share to exclude amortization, stock compensation, restructuring, foreign exchange and transaction-related / integrated-related adjustments.

    ICON plc (NASDAQ:ICLR), a world-leading healthcare intelligence and clinical research organization, today reported its financial results for the first quarter ended March 31, 2024.

    CEO, Dr. Steve Cutler commented, "ICON reported a strong start to the year in quarter one, with revenue growth of 6% year over year, and net bookings up 10% over quarter one 2023, resulting in a net book to bill ratio of 1.27 times. Adjusted earnings per share grew a robust 20% on a year over year basis, reflecting our efficient service delivery and strong cost control. Our performance is reflective of the current favorable demand trends across our industry, as well as the further development of strategic customer partnerships.

    With the positive results in quarter one and consistent outlook for the year, we are updating our full-year financial guidance range for 2024, with revenue in the range of $8,480 - $8,720 million, representing growth of 6% year over year at the midpoint, and adjusted earnings per share of $14.65 - $15.15, an increase of 16% year over year at the midpoint of the range."

    First Quarter 2024 Results

    Gross business wins in the first quarter were $3,114 million and cancellations were $460 million. This resulted in net business wins of $2,654 million and a book to bill of 1.27.

    Revenue for the first quarter was $2,090.4 million. This represents an increase of 5.7% on prior year revenue or 5.4% on a constant currency basis.

    GAAP net income was $187.4 million resulting in $2.25 diluted earnings per share in quarter one 2024 compared to $1.41 diluted earnings per share in quarter one 2023. Adjusted net income for the quarter was $288.5 million resulting in an adjusted diluted earnings per share of $3.47 compared to $2.90 per share for the first quarter 2023.

    Adjusted EBITDA for the first quarter was $444.0 million or 21.2% of revenue, a year-on-year increase of 11.3%.

    The effective tax rate on adjusted net income in quarter one 2024 was 16.5%.

    Cash generated from operating activities for the quarter was $327.1 million. During the quarter $27.2 million was spent on capital expenditure. At March 31, 2024, the Group had cash and cash equivalents of $396.1 million, compared to cash and cash equivalents of $378.1 million at December 31, 2023 and $279.9 million at March 31, 2023. $50 million of the revolving credit facility was drawn down in the quarter and $55 million was repaid. Additionally, a $275.0 million Term Loan B payment was made during the quarter resulting in a net indebtedness of $3.1 billion at March 31, 2024.

    Other Information

    In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this press release contains certain non-GAAP financial measures, including adjusted EBITDA, adjusted net income and adjusted diluted earnings per share. Adjusted EBITDA, adjusted net income and adjusted diluted earnings per share exclude amortization, stock compensation, foreign exchange gains and losses, restructuring and transaction-related / integration-related adjustments. While non-GAAP financial measures are not superior to or a substitute for the comparable GAAP measures, ICON believes certain non-GAAP information is useful to investors for historical comparison purposes.

    ICON will hold a conference call on April 25, 2024 at 08:00 EDT [13:00 Ireland & UK]. This call and linked slide presentation can be accessed live from our website at http://investor.iconplc.com. A recording will also be available on the website for 90 days following the call. In addition, a calendar of company events, including upcoming conference presentations, is available on our website, under "Investors". This calendar will be updated regularly.

    This press release contains forward-looking statements, including statements about our financial guidance. These statements are based on management's current expectations and information currently available, including current economic and industry conditions. These statements are not guarantees of future performance or actual results, and actual results, developments and business decisions may differ from those stated in this press release. The forward-looking statements are subject to future events, risks, uncertainties and other factors that could cause actual results to differ materially from those projected in the statements, including, but not limited to, the ability to enter into new contracts, maintain client relationships, manage the opening of new offices and offering of new services, the integration of new business mergers and acquisitions, as well as other economic and global market conditions and other risks and uncertainties detailed from time to time in SEC reports filed by ICON, all of which are difficult to predict and some of which are beyond our control. For these reasons, you should not place undue reliance on these forward-looking statements when making investment decisions. The word "expected" and variations of such words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are only as of the date they are made and we do not undertake any obligation to update publicly any forward-looking statement, either as a result of new information, future events or otherwise. More information about the risks and uncertainties relating to these forward-looking statements may be found in SEC reports filed by ICON, including its Form 20-F, F-1, F-4, S-8, F-3 and certain other reports, which are available on the SEC's website at http://www.sec.gov.

    * Our full-year 2024 guidance adjusted earnings per share measures are provided on a non-GAAP basis because the company is unable to predict with a reasonable degree of certainty certain items contained in the GAAP measures without unreasonable efforts. For the same reasons, the company is unable to address the probable significance of the unavailable information.

    ICON plc is a world-leading healthcare intelligence and clinical research organization. From molecule to medicine, we advance clinical research providing outsourced services to pharmaceutical, biotechnology, medical device and government and public health organizations. We develop new innovations, drive emerging therapies forward and improve patient lives. With headquarters in Dublin, Ireland, ICON employed approximately 41,150 employees in 102 locations in 54 countries as at March 31, 2024. For further information about ICON, visit: www.iconplc.com.

    ICON/ICLR-F

    ICON plc

    CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

    FOR THE THREE MONTHS ENDED MARCH 31, 2024 AND MARCH 31, 2023

    (UNAUDITED)

     

     

    Three Months Ended

     

    March 31, 2024

     

    March 31, 2023

     

    (in thousands except share and per share data)

     

     

     

     

    Revenue

    $

    2,090,386

     

     

    $

    1,978,578

     

     

     

     

     

    Costs and expenses:

     

     

     

    Direct costs (excluding depreciation and amortization)

     

    1,471,367

     

     

     

    1,395,546

     

    Selling, general and administrative

     

    177,350

     

     

     

    200,006

     

    Depreciation and amortization

     

    149,181

     

     

     

    145,126

     

    Transaction and integration related

     

    6,991

     

     

     

    11,382

     

    Restructuring

     

    —

     

     

     

    9,729

     

    Total costs and expenses

     

    1,804,889

     

     

     

    1,761,789

     

     

     

     

     

    Income from operations

     

    285,497

     

     

     

    216,789

     

    Interest income

     

    1,930

     

     

     

    1,072

     

    Interest expense

     

    (71,665

    )

     

     

    (86,551

    )

     

     

     

     

    Income before income tax expense

     

    215,762

     

     

     

    131,310

     

    Income tax expense

     

    (28,324

    )

     

     

    (14,273

    )

     

     

     

     

    Income before share of losses from equity method investments

     

    187,438

     

     

     

    117,037

     

    Share of losses from equity method investments

     

    —

     

     

     

    (383

    )

    Net income

    $

    187,438

     

     

    $

    116,654

     

     

     

     

     

    Net income per Ordinary Share:

     

     

     

     

     

     

     

    Basic

    $

    2.27

     

     

    $

    1.43

     

    Diluted

    $

    2.25

     

     

    $

    1.41

     

     

     

     

     

    Weighted average number of Ordinary Shares outstanding:

     

     

     

     

     

     

     

    Basic

     

    82,579,203

     

     

     

    81,784,389

     

    Diluted

     

    83,249,303

     

     

     

    82,605,659

     

    ICON plc

    CONDENSED CONSOLIDATED BALANCE SHEETS

    AS AT MARCH 31, 2024 AND DECEMBER 31, 2023

    (UNAUDITED)

     

    March 31, 2024

     

    December 31, 2023

    ASSETS

    (in thousands)

    Current assets:

     

     

     

    Cash and cash equivalents

    $

    396,082

     

     

    $

    378,102

     

    Available for sale investments

     

    1,955

     

     

     

    1,954

     

    Accounts receivable, net of allowance for credit losses

     

    1,862,468

     

     

     

    1,790,322

     

    Unbilled revenue

     

    993,141

     

     

     

    951,936

     

    Other receivables

     

    76,638

     

     

     

    65,797

     

    Prepayments and other current assets

     

    149,127

     

     

     

    132,105

     

    Income taxes receivable

     

    75,544

     

     

     

    91,254

     

    Total current assets

    $

    3,554,955

     

     

    $

    3,411,470

     

    Non-current assets:

     

     

     

    Property, plant and equipment

     

    353,302

     

     

     

    361,184

     

    Goodwill

     

    9,018,301

     

     

     

    9,022,075

     

    Intangible assets

     

    3,748,939

     

     

     

    3,855,865

     

    Operating right-of-use assets

     

    159,620

     

     

     

    140,333

     

    Other receivables

     

    87,193

     

     

     

    78,470

     

    Deferred tax asset

     

    74,777

     

     

     

    73,662

     

    Investments in equity- long term

     

    51,164

     

     

     

    46,804

     

    Total Assets

    $

    17,048,251

     

     

    $

    16,989,863

     

     

     

     

     

    LIABILITIES AND SHAREHOLDERS' EQUITY

     

     

     

    Current liabilities:

     

     

     

    Accounts payable

    $

    113,579

     

     

    $

    131,584

     

    Unearned revenue

     

    1,709,938

     

     

     

    1,654,507

     

    Other liabilities

     

    1,000,760

     

     

     

    915,399

     

    Income taxes payable

     

    41,905

     

     

     

    13,968

     

    Current bank credit lines and loan facilities

     

    79,762

     

     

     

    110,150

     

    Total current liabilities

    $

    2,945,944

     

     

    $

    2,825,608

     

    Non-current liabilities:

     

     

     

    Non-current bank credit lines and loan facilities

     

    3,419,734

     

     

     

    3,665,439

     

    Lease liabilities

     

    145,542

     

     

     

    126,321

     

    Non-current other liabilities

     

    45,988

     

     

     

    45,998

     

    Non-current income taxes payable

     

    188,876

     

     

     

    186,654

     

    Deferred tax liability

     

    869,520

     

     

     

    899,100

     

    Commitments and contingencies

     

    —

     

     

     

    —

     

    Total Liabilities

    $

    7,615,604

     

     

    $

    7,749,120

     

     

     

     

     

    Shareholders' Equity:

     

     

     

    Ordinary shares, par value 6 euro cents per share; 100,000,000 shares authorized,

     

     

     

    82,683,805 shares issued and outstanding at March 31, 2024 and

     

     

     

    82,495,086 shares issued and outstanding at December 31, 2023

     

    6,711

     

     

     

    6,699

     

    Additional paid-in capital

     

    6,970,079

     

     

     

    6,942,669

     

    Other undenominated capital

     

    1,162

     

     

     

    1,162

     

    Accumulated other comprehensive loss

     

    (166,462

    )

     

     

    (143,506

    )

    Retained earnings

     

    2,621,157

     

     

     

    2,433,719

     

    Total Shareholders' Equity

    $

    9,432,647

     

     

    $

    9,240,743

     

    Total Liabilities and Shareholders' Equity

    $

    17,048,251

     

     

    $

    16,989,863

     

     

     

     

     

     

     

     

     

    ICON plc

    CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

    FOR THE THREE MONTHS ENDED MARCH 31, 2024 AND MARCH 31, 2023

    (UNAUDITED)

     

     

    Three Months Ended

     

    March 31, 2024

     

    March 31, 2023

     

    (in thousands)

    Cash flows from operating activities:

     

     

     

    Net income

    $

    187,438

     

     

    $

    116,654

     

    Adjustments to reconcile net income to net cash provided by operating activities:

     

     

     

    Depreciation and amortization expense

     

    149,181

     

     

     

    145,126

     

    Impairment of long lived assets

     

    —

     

     

     

    6,933

     

    Reduction in carrying value of operating right-of-use assets

     

    11,472

     

     

     

    11,304

     

    Loss on equity method investments

     

    —

     

     

     

    383

     

    Amortization of financing costs and debt discount

     

    3,907

     

     

     

    4,497

     

    Stock compensation expense

     

    13,181

     

     

     

    14,759

     

    Deferred tax benefit

     

    (35,145

    )

     

     

    (43,823

    )

    Unrealized foreign exchange movements

     

    (1,027

    )

     

     

    (1,319

    )

    Other non-cash items

     

    4,629

     

     

     

    17,534

     

    Changes in operating assets and liabilities:

     

     

     

    Accounts receivable

     

    (80,431

    )

     

     

    (93,259

    )

    Unbilled revenue

     

    (42,546

    )

     

     

    (18,346

    )

    Unearned revenue

     

    56,485

     

     

     

    80,990

     

    Other net assets

     

    59,932

     

     

     

    (65,933

    )

    Net cash provided by operating activities

     

    327,076

     

     

     

    175,500

     

    Cash flows from investing activities:

     

     

     

    Purchase of property, plant and equipment

     

    (27,152

    )

     

     

    (26,744

    )

    Purchase of subsidiary undertakings (net of cash acquired)

     

    (7,831

    )

     

     

    —

     

    Sale of available for sale investments

     

    1,005

     

     

     

    482

     

    Purchase of available for sale investments

     

    (1,006

    )

     

     

    (422

    )

    Purchase of investments in equity - long term

     

    (4,381

    )

     

     

    (1,358

    )

    Net cash used in investing activities

     

    (39,365

    )

     

     

    (28,042

    )

    Cash flows from financing activities:

     

     

     

    Drawdown of credit lines and loan facilities

     

    50,000

     

     

     

    180,000

     

    Repayment of credit lines and loan facilities

     

    (330,000

    )

     

     

    (350,000

    )

    Proceeds from exercise of equity compensation

     

    16,305

     

     

     

    12,940

     

    Share issue costs

     

    (4

    )

     

     

    (4

    )

    Net cash used in by financing activities

     

    (263,699

    )

     

     

    (157,064

    )

    Effect of exchange rate movements on cash

     

    (6,032

    )

     

     

    718

     

    Net increase / (decrease) in cash and cash equivalents

     

    17,980

     

     

     

    (8,888

    )

    Cash and cash equivalents at beginning of period

     

    378,102

     

     

     

    288,768

     

    Cash and cash equivalents at end of period

    $

    396,082

     

     

    $

    279,880

     

    ICON plc

    RECONCILIATION OF NON-GAAP MEASURES

    FOR THE THREE MONTHS ENDED MARCH 31, 2024 AND MARCH 31, 2023

    (UNAUDITED)

     

    Three Months Ended

     

    March 31, 2024

     

    March 31, 2023

     

    (in thousands except share and per share data)

     

     

     

     

    Adjusted EBITDA

     

     

     

    Net income

    $

    187,438

     

     

    $

    116,654

     

    Share of losses from equity method investments

     

    —

     

     

     

    383

     

    Income tax expense

     

    28,324

     

     

     

    14,273

     

    Net interest expense

     

    69,735

     

     

     

    85,479

     

    Depreciation and amortization

     

    149,181

     

     

     

    145,126

     

    Stock-based compensation expense (a)

     

    13,181

     

     

     

    14,759

     

    Foreign currency (gains)/losses, net (b)

     

    (10,814

    )

     

     

    1,338

     

    Restructuring (c)

     

    —

     

     

     

    9,729

     

    Transaction and integration related costs (d)

     

    6,991

     

     

     

    11,382

     

    Adjusted EBITDA

    $

    444,036

     

     

    $

    399,123

     

     

     

     

     

    Adjusted net income and adjusted diluted net income per Ordinary Share

     

     

     

    Net income

    $

    187,438

     

     

    $

    116,654

     

    Income tax expense

     

    28,324

     

     

     

    14,273

     

    Amortization

     

    116,498

     

     

     

    114,678

     

    Stock-based compensation expense (a)

     

    13,181

     

     

     

    14,759

     

    Foreign currency (gains)/losses, net (b)

     

    (10,814

    )

     

     

    1,338

     

    Restructuring (c)

     

    —

     

     

     

    9,729

     

    Transaction and integration related costs (d)

     

    6,991

     

     

     

    11,382

     

    Transaction-related financing costs (e)

     

    3,907

     

     

     

    4,498

     

    Adjusted tax expense (f)

     

    (57,012

    )

     

     

    (47,469

    )

    Adjusted net income

    $

    288,513

     

     

    $

    239,842

     

     

     

     

     

    Diluted weighted average number of Ordinary Shares outstanding

     

    83,249,303

     

     

     

    82,605,659

     

     

     

     

     

    Adjusted diluted net income per Ordinary Share

    $

    3.47

     

     

    $

    2.90

     

     

     

     

     

    (a)

    Stock-based compensation expense represents the amount of recurring expense related to the company's equity compensation programs (inclusive of employer related taxes).

    (b)

    Foreign currency (gains)/losses, net relates to gains or losses that arise in connection with the revaluation of non-US dollar denominated assets and liabilities. We exclude these gains and losses from adjusted EBITDA and adjusted net income because fluctuations from period- to- period do not necessarily correspond to changes in our operating results.

    (c)

    Restructuring relates to charges incurred in connection with the company's realignments of its workforce, with the elimination of redundant positions as well as reviewing its global office footprint and optimizing its locations to best fit the requirements of the company.

    (d)

    Transaction and integration related costs include expenses/credits associated with our acquisitions and any other costs incurred directly related to the integration of these acquisitions.

    (e)

    Transaction-related financing costs includes costs incurred in connection with changes to our long-term debt and amortization of financing fees. We exclude these costs from adjusted EBITDA and adjusted net income because they result from financing decisions rather than from decisions made related to our ongoing operations.

    (f)

    Represents the tax effect of adjusted pre-tax income at our estimated effective tax rate.

    Source: ICON plc

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240424083968/en/

    Get the next $ICLR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ICLR

    DatePrice TargetRatingAnalyst
    1/8/2026$222.00Buy → Hold
    Truist
    12/15/2025$195.00Buy → Neutral
    BofA Securities
    11/13/2025$175.00Market Perform
    BMO Capital Markets
    9/9/2025$175.00Buy → Hold
    Jefferies
    9/3/2025$236.00Neutral → Buy
    Rothschild & Co Redburn
    8/21/2025$200.00Buy → Neutral
    Citigroup
    7/24/2025$224.00Neutral → Outperform
    Robert W. Baird
    4/29/2025$150.00Overweight → Neutral
    Analyst
    More analyst ratings

    $ICLR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ICON's Accellacare Site Network Expands Oncology Research Capabilities With New Cancer Institute Partnership

    ICON plc (NASDAQ:ICLR) today announced a significant expansion of oncology research capabilities within its Accellacare Site Network through the opening of the Brian Moran Cancer Institute at Duly Health and Care in Illinois. The new institute strengthens Accellacare's ability to support oncology clinical trials and broaden access to innovative cancer treatments for patients. The Brian Moran Cancer Institute includes: ‒ 14 medical oncologists ‒ Three radiation oncologists ‒ Nine fellowship-trained surgical specialists in urologic oncology, breast surgery, colorectal surgery, endocrine surgery, and general surgical oncology This development builds on Accellacare's existing oncology exp

    1/27/26 7:15:00 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    ICON 2025 global biotech survey solidifies China dominance and highlights opportunities for Western biotechs to stay competitive

    ICON plc (NASDAQ:ICLR), a world-leading clinical research organisation, today released findings from two biotech sector surveys. The first survey focused on global biotech trends and is an update of our 2023 survey, while the second survey focused exclusively on trends in the rapidly growing Chinese biotech market. In total, both surveys captured insights from more than 260 biotech professionals and venture capital executives across the US, Europe, Asia-Pacific (APAC) and the Middle East. ICON's global biotech sector survey of 163 biotech respondents highlights the resilience of the industry, driven by investment in APAC markets and shifts in R&D priorities since its last survey in 2023. I

    12/9/25 7:15:00 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    ICON Survey Reveals Increasing Clinical Trial Startup Delays, Underscoring Need for Human-Centred Site Activation Solutions

    ICON plc (NASDAQ:ICLR), a world-leading clinical research organisation, today announced results of its latest industry survey, examining the challenges clinical trial sites face during study startup. The findings underscore the need for a site-centric, collaborative approach to overcome bottlenecks and enhance trial activation timelines. The survey, conducted in June 2025 among just over 100 principal investigators and senior clinical trial site personnel, gathered perspectives from a wide range of clinical trial sites and is not limited to studies managed by ICON. It reveals widespread sentiment that sites are increasingly burdened by operational bottlenecks, contract and budget delays, a

    12/2/25 7:15:00 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ICLR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    $ICLR
    SEC Filings

    View All

    ICON plc downgraded by Truist with a new price target

    Truist downgraded ICON plc from Buy to Hold and set a new price target of $222.00

    1/8/26 8:39:35 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    ICON plc downgraded by BofA Securities with a new price target

    BofA Securities downgraded ICON plc from Buy to Neutral and set a new price target of $195.00

    12/15/25 9:55:49 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    BMO Capital Markets initiated coverage on ICON plc with a new price target

    BMO Capital Markets initiated coverage of ICON plc with a rating of Market Perform and set a new price target of $175.00

    11/13/25 9:13:59 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form 6-K filed by ICON plc

    6-K - ICON PLC (0001060955) (Filer)

    1/7/26 4:15:46 PM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SCHEDULE 13G filed by ICON plc

    SCHEDULE 13G - ICON PLC (0001060955) (Subject)

    11/14/25 12:59:35 PM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SCHEDULE 13G filed by ICON plc

    SCHEDULE 13G - ICON PLC (0001060955) (Subject)

    11/12/25 9:33:32 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ICLR
    Leadership Updates

    Live Leadership Updates

    View All

    ICON Announces CEO Transition

    ICON plc (NASDAQ:ICLR), a world-leading clinical research organisation, today announced that Dr. Steve Cutler has informed the Board of his decision to retire as Chief Executive Officer and the Board has appointed Mr. Barry Balfe, ICON's Chief Operating Officer, to succeed Dr. Cutler as Chief Executive Officer effective 1 October 2025. Mr. Balfe has also been appointed to the Board. Dr. Cutler will continue to serve on the Board as a non-executive director to facilitate a smooth transition. Mr. Balfe has deep knowledge of the CRO industry and has served as ICON's Chief Operating Officer since January 2025. Prior to his appointment as Chief Operating Officer, Mr. Balfe was appointed to the

    9/4/25 8:00:00 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    ICON Announces Results of Annual General Meeting

    ICON plc (NASDAQ:ICLR), a world-leading clinical research organisation powered by healthcare intelligence, today announced that all resolutions at the Annual General Meeting of the company (AGM) held on July 22, 2025 were duly passed by shareholders. These resolutions were set out in the Notice of the AGM sent to shareholders dated June 11, 2025 and are available on the ICON plc website. Forms of Proxy were received by ICON plc before the meeting, appointing proxies and giving them the following voting instructions: RESOLUTION NUMBER RESOLUTION     TOTAL NUMBER OF VOTES     VOTE FOR     VOTE AGAINST     VOTE WITHHELD                   1.1

    7/23/25 4:20:00 PM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    Anne Whitaker Appointed as Non-Executive Director

    MELBOURNE, Australia and INDIANAPOLIS, April 04, 2025 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ:TLX, Telix, the Company) today announces the appointment of Anne Whitaker as a Non-Executive Director (NED) based in the United States, effective 7 April 20251. Ms. Whitaker is a seasoned healthcare leader and advisor with over 30 years' global corporate experience spanning large pharmaceutical, biotech and speciality pharmaceutical companies, including clinical research and manufacturing organizations. She has held Board positions on a range of Nasdaq-listed clinical and commercial stage life sciences companies. Ms. Whitaker is currently serving as a NED at Icon PLC

    4/3/25 6:13:56 PM ET
    $ICLR
    $TLX
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $ICLR
    Financials

    Live finance-specific insights

    View All

    ICON Reports Third Quarter 2025 Results

    Highlights Quarter three revenue was $2,042.8 million representing an increase of 1.3% on quarter two 2025. Net income for the quarter was $2.4 million or $0.03 per diluted share. Quarter three adjusted EBITDA was $396.7 million or 19.4% of revenue, representing an increase of 0.2% on quarter two 2025. Quarter three adjusted net income was $258.8 million or $3.31 per diluted ordinary share. Gross business wins in the quarter of $2,986 million, representing an increase of 0.7% on quarter two 2025. Net business wins in the quarter of $2,086 million, representing an increase of 1.4% on quarter two 2025; a net book to bill in the quarter of 1.02. Net debt was $2.9 bil

    10/22/25 4:25:00 PM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    ICON plc Schedules Third Quarter 2025 Earnings Conference Call

    ICON plc, (NASDAQ:ICLR) a world-leading clinical research organisation, today announced that it will release its financial results for the third quarter 2025 after the market closes on Wednesday, October 22, 2025. The company will hold a conference call and webcast to discuss its financial results and performance on Thursday, October 23, 2025 at 8:00am ET. Any changes to this event and links to the live webcast will be posted on the Investor section of our website under "Events". A webcast replay of the conference call will be available approximately one hour following the conclusion of the call. About ICON plc ICON plc is a world-leading clinical research organisation. From molecule

    9/24/25 9:00:00 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    ICON Reports Second Quarter 2025 Results

    Highlights Gross business wins in the quarter of $2,966 million, representing an increase of 10.6% on quarter one 2025. Net business wins in the quarter of $2,057 million; a net book to bill in the quarter of 1.02. Quarter two revenue was $2,017.4 million representing an increase of 0.8% on quarter one 2025. Net income for the quarter was $183.0 million or $2.30 per diluted share, an increase of 30.7% on quarter two 2024 diluted earnings per ordinary share. Quarter two adjusted EBITDA was $396.0 million or 19.6% of revenue, representing an increase of 1.4% on quarter one 2025. Quarter two adjusted net income was $259.5 million or $3.26 per diluted ordinary share. Net de

    7/23/25 4:15:00 PM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    $ICLR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by ICON plc

    SC 13G/A - ICON PLC (0001060955) (Subject)

    11/12/24 11:54:03 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G/A filed by ICON plc (Amendment)

    SC 13G/A - ICON PLC (0001060955) (Subject)

    2/9/24 11:49:03 AM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care

    SEC Form SC 13G/A filed by ICON plc (Amendment)

    SC 13G/A - ICON PLC (0001060955) (Subject)

    1/30/24 12:11:57 PM ET
    $ICLR
    Biotechnology: Commercial Physical & Biological Resarch
    Health Care